FABP5 and cancer: A comparison of normal cells with benign hyperplasia indicates that FABP5 is ubiquitously overexpressed in most the cancers including breast cancer, cervical cancer (CCa), endometrial cancer (EC), head and neck squamous cell carcinoma (HNSC), prostate cancer (PCa), hepatocellular carcinoma (HCC), tongue carcinoma, esophageal cancer (ESCA), clear cell renal cell carcinoma (ccRCC), stomach adenocarcinoma (STAD), and lung squamous cell carcinoma (LUSC) (Table 2).